Propranolol induced hypoglycemia

Abstract

ince 2008, propranolol has become the first line therapy for infantile hemangiomas. Due to the fact that infantile hemangiomas are the most common vascular tumors of infancy, the use of systemic propranolol has been dramatically increased in the last few years. The reported adverse effects of propranolol in the treatment of infantile hemangiomas included symptomatic hypoglycemia. In this review we will summarize those reports and will offer guidelines for prevention of hypoglycemia secondary to propranolol therapy.